Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of ceftolozane + tazobactam versus meropenem for ventilated hospital-acquired bacterial pneumonia
MOH_2017-02-07_000079Phase 3Completed
- Sponsor
- Cubist Pharmaceuticals, Inc.
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) comparing Ceftolozane/tazobactam arm with Meropenem arm (2 arms). Primary endpoint: Primary endpoint not reported in registry entry. Started May 2014; status: completed.
02
Drugs
ceftolozane + tazobactammeropenem
03
Conditions
ventilator-associated pneumonia (VAP)hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on MOH_2017-02-07_000079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-07_000079.